Results 1 to 10 of about 316,116 (209)

SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity [PDF]

Frontiers in Immunology, 2022
SOT101 is a superagonist fusion protein of interleukin (IL)-15 and the IL-15 receptor α (IL-15Rα) sushi+ domain, representing a promising clinical candidate for the treatment of cancer.
Zuzana Antosova, Nada Podzimkova, Nada Podzimkova, Jakub Tomala, Katerina Augustynkova, Katerina Sajnerova, Eva Nedvedova, Milada Sirova, Guy de Martynoff, David Bechard, Ulrich Moebius, Marek Kovar, Radek Spisek, Radek Spisek, Irena Adkins, Irena Adkins   +15 more
doaj   +2 more sources

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia [PDF]

Journal of Hematology & Oncology, 2017
Background The CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Manoj K. Kashyap, Carlos I. Amaya-Chanaga, Deepak Kumar, Brett Simmons, Nanni Huser, Yin Gu, Max Hallin, Kevin Lindquist, Rolla Yafawi, Michael Y. Choi, Ale-Ali Amine, Laura Z. Rassenti, Cathy Zhang, Shu-Hui Liu, Tod Smeal, Valeria R. Fantin, Thomas J. Kipps, Flavia Pernasetti, Januario E. Castro   +18 more
doaj   +6 more sources

Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies [PDF]

eLife, 2021
A prerequisite for the design of an HIV vaccine that elicits protective antibodies is understanding the developmental pathways that result in desirable antibody features. The development of antibodies that mediate antibody-dependent cellular cytotoxicity
Laura E Doepker, Sonja Danon, Elias Harkins, Duncan K Ralph, Zak Yaffe, Meghan E Garrett, Amrit Dhar, Cassia Wagner, Megan M Stumpf, Dana Arenz, James A Williams, Walter Jaoko, Kishor Mandaliya, Kelly K Lee, Frederick A Matsen IV, Julie M Overbaugh   +15 more
doaj   +2 more sources

The Anti-SLAMF7 Antibody, Elotuzumab, Induces Antibody-Dependent Cellular Cytotoxicity Against CLL Cell Lines [PDF]

Molecules
SLAMF7, also known as CD319, a SLAM (signaling lymphocytic activation molecule) family receptor, is relatively weakly expressed on chronic lymphocytic leukemia (CLL) B cells.
Dominik Kľoc, Bianca Dubiková, Simona Žiláková, Ján Sykora, Michaela Šuliková, Slavomír Kurhajec, Ján Sabo, Tomáš Guman, Marek Šarišský   +8 more
doaj   +2 more sources

Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review

Frontiers in Oncology, 2023
Therapeutic monoclonal antibodies (mAbs) are standard care for many B-cell haematological cancers. The modes of action for these mAbs include: induction of cancer cell lysis by activating Fcγ-receptors on innate immune cells; opsonising target cells for ...
Harrison D. Collier-Bain, Frankie F. Brown, Frankie F. Brown, Adam J. Causer, Annabelle Emery, Rebecca Oliver, Rebecca Oliver, Sally Moore, James Murray, James E. Turner, James E. Turner, John P. Campbell   +11 more
doaj   +1 more source

Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity

Frontiers in Immunology, 2021
The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be ...
Christian Binder, Christian Binder, Felix Sellberg, Felix Sellberg, Filip Cvetkovski, Stefan Berg, Erik Berglund, Erik Berglund, David Berglund, David Berglund   +9 more
doaj   +1 more source

Considerations of Antibody Geometric Constraints on NK Cell Antibody Dependent Cellular Cytotoxicity

Frontiers in Immunology, 2020
It has been well-established that antibody isotype, glycosylation, and epitope all play roles in the process of antibody dependent cellular cytotoxicity (ADCC).
Charles D. Murin
doaj   +1 more source

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma

Frontiers in Immunology, 2023
BackgroundDespite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel therapies are urgently needed. As the anti-CD20 antibody rituximab and the CD19-targeting antibody
Maria Patra-Kneuer, Gaomei Chang, Wendan Xu, Christian Augsberger, Michael Grau, Myroslav Zapukhlyak, Kristina Ilieva, Karin Landgraf, Doris Mangelberger-Eberl, Kasra Yousefi, Philipp Berning, Katrin S. Kurz, German Ott, Pavel Klener, Pavel Klener, Cyrus Khandanpour, Cyrus Khandanpour, Pedro Horna, Jürgen Schanzer, Stefan Steidl, Jan Endell, Christina Heitmüller, Georg Lenz   +22 more
doaj   +1 more source

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Haematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst, Tuna Mutis   +7 more
doaj   +1 more source

From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement

Frontiers in Immunology, 2022
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclonal antibodies (mAbs), and ...
Loïs Coënon, Loïs Coënon, Martin Villalba, Martin Villalba   +3 more
doaj   +1 more source